New Delhi, February 9: Mumbai based global pharma company Glenmark launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult Covid-19 patients. As part of the accelerated approval procedure, Glenmark acquired manufacturing and marketing authorisation for Nitric Oxide Nasal Spray from India's drug regulator, Drugs Controller General of India (DCGI). As per the official statement, "Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 per cent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in Covid-19 patients. Glenmark to market NONS under the brand name FabiSpray."